MXPA01005192A - Coating useful as a dispenser of an active ingredient on dressings and bandages - Google Patents

Abstract

The dressings of the invention comprise at least two components:an absorbent substrate having a first skin-facing surface and a second opposing surface;and a discontinuous coating of a semi-solid composition having an ointment-like feel overlying a portion of the first surface of said absorbent substrate. The absorbent substrate is useful as a passive dispenser of at least one active ingredient that may be contained therein. The discontinuous coating is essentially non-adherent to the skin and is useful as an active dispenser of at least one active ingredient that may be contained therein. In preferred embodiments the dressing of the invention contains at least one and more preferably at least two active ingredients intended to provide therapeutic benefit to the skin.

Description

USEFUL COATING AS DISPENSER OF AN ACTIVE INGREDIENT IN APPLIANCES AND BANDAGES FIELD OF THE INVENTION The present invention is directed to a dressing, particularly for wounds, which comprises an absorbent substrate and a discontinuous coating of a composition having an ointment-like feel. The dressing is useful for absorbing body exudates, particularly wound exudates, and for dispensing active ingredients, eg, therapeutic ingredient, to the skin without substantial loss of the absorption layer. The apposites of the invention and bandages derived therefrom can be easily and comfortably removed from the skin when desired without re-traumatizing the site of a wound.

BACKGROUND OF THE INVENTION AND PREVIOUS TECHNIQUE The bandages and wound dressings typically comprise an absorbent pad that absorbs exudate from a wound. The absorbent pad is typically constructed of a fibrous nonwoven material. A problem with such absorbent dressings is that the fibers of the absorbent pad may be included in the healing wound, making it difficult to painlessly remove the bandage without traumatizing the wound. To overcome this problem, the absorbent pads used in bandages are typically covered with a porous plastic film that prevents the pad from adhering to the wound. It is a common practice to treat wounds with ointment-like compositions. Ointments are often used because they tend to act as balms that relieve the wound. In addition, the ointments can be combined with active ingredients such as antibiotics to provide therapeutic properties that help control infection and heal the wound. Because the ointments are usually viscous or semi-solid liquids, rather than solid materials, the therapeutic materials present in ointment are usually readily available to the wound only by contacting the wound with the ointment, even in the absence of moisture such as exudate. wet from the wound. After ointment treatment, the wounds are typically covered with an adhesive bandage. The use of ointment in conjunction with a bandage is also beneficial because the ointment tends to prevent the fibers of an absorbent pad present in a bandage from adhering to the site of the wound. Although effective in promoting wound healing, a problem with such treatment regimens is that they are relatively inconvenient and disordered.

An advance in the technique of wound treatment was the development of structured occlusive apposites of the type described in the U.S. patent. 5,814,031, which is incorporated herein by reference in its entirety. The inserts of the '031 patent comprise a support material and an occlusive composition that covers the support material. Examples of support materials described in the '031 patent include woven, spun and non-woven fabrics. Although these support materials may have some absorption capacity, the presence of the occlusive composition covering the support material tends to block the support, and prevent it from absorbing moisture-containing fluids such as wound exudate. Japanese Patent Application Laid Open 56-2909 discloses an adhesive drug material that is administered in the form of a poultice or drug patch. The adhesive drug material is applied to an air-permeable base material in the form of spots, networks or lines, for example, by a printing method. It is said that the application of adhesive drug material to base material in the discontinuous pattern prevents damage to the skin form maceration. However, it would be expected that the use of an adhesive material in the wound area of a wound dressing is undesirable, since it would be expected that contact of the wound with an adhesive composition will re-traumatize the wound when the dressing it is removed. The patent of the United Kingdom 2, 221,620 discloses a hemostatic wound dressing material of a fibrous substrate having a discontinuous coating of an aqueous solution of an alkylate material deposited on the surface thereof. The final step in the manufacture of the dressing is to evaporate the water from the alkylate solution such as, for example, by passing the dressing material through temperature controlled ovens. Although the dressings described in the '620 patent may possess good hemostatic properties, they are not expected to have the relieving properties of ointment-containing dressings. Furthermore, it would not be expected that any active agent present in such a dressing would be readily available to a wound without moisture such as that which is contained in the exudate of a wound. The patents of E.U.A. 4,166,108 and 4,331, 653 disclose compositions in the form of a lotion or cream that reduces skin hemorrhage. It is noted that these compositions can be impregnated in pre-packaged bandages. Again, the impregnation of these compositions in bandages would be expected to block the absorption capacity of the bandages, and thus prevent the bandages from absorbing the exudate from the wound. The patent of E.U.A. 5,147, 339 describes dressings for the treatment of wounds comprising corpuscles containing bioactive substances in a hydrophilic medium dispersed in a solid continuous matrix, hydrophobic and insoluble in water. Because the active substance is distributed in a solid matrix, it is expected that wound exudate or other substances containing moisture will release the bioactive substance from the matrix and in contact with the wound. In addition, the patent application '339 would not be expected to have the wound-relieving properties of ointment-containing dressings. An object of the present invention is to provide a dressing for the treatment of wounds that can be easily removed from the site of a wound when desired, without re-traumatizing the wound. Another object of the invention is to provide a dressing that has a relief effect on wounds. Another objective of the invention is to provide a dressing that is capable of delivering active therapeutic ingredient to the site of a wound. Another object of the invention is to provide a dressing that is capable of delivering multiple therapeutic ingredients to the site of a wound, even when said ingredients are not mutually compatible. Another object of the invention is to provide a dressing that is capable of absorbing the exudate from a wound. Another object of the invention is to provide a dressing containing a relief composition similar to ointment, as long as it is capable of absorbing the exudate from the wound. Another object of the invention is to provide a dressing that exhibits all of the attributes mentioned above, or a combination thereof. Another object of the invention is to provide a dressing with the attributes previously, in the form of an adhesive bandage.

Other objects will be apparent in the following description of the invention.

BRIEF DESCRIPTION OF THE INVENTION The apposites of the invention comprise at least two components: a. an absorbent substrate having a first surface facing the skin and a second opposing surface; b. a discontinuous coating of a semisolid composition having a ointment-like feel that covers a portion of the first surface of said absorbent substrate. The absorbent substrate in the dressing of the invention is useful as a passive dispenser of at least one active ingredient. The discontinuous coating is essentially non-adherent to the skin, and is useful as an active dispenser of at least one active ingredient. In a preferred embodiment, the dressing of the invention contains at least one active ingredient intended to provide therapeutic benefit to the skin. In another preferred embodiment, the dressing of the invention contains at least two active ingredients, the first being substantially contained within the absorbent substrate, and a second active ingredient contained substantially within the discontinuous coating.

Also included within the scope of the invention are adhesive bandages comprising a reinforcing material, an adhesive layer and the dressings listed above.

BRIEF DESCRIPTION OF THE DRAWINGS Figure 1A is a top plan view of a mode of the dressing of the invention. Figure 1 B is a cross-sectional view of the dressing of Figure 1A taken along line 2-2 of Figure 1A. Figure 2A shows a configuration of the discontinuous coating of the dressing of the invention. Figure 2B shows an alternative configuration of the discontinuous coating of the dressing of the invention. Figure 2C shows another alternative configuration of the discontinuous coating of the dressing of the invention. Figure 2D shows another alternative configuration of the discontinuous coating of the dressing of the invention. Figure 2E shows another alternative configuration of the discontinuous coating of the dressing of the invention. Figure 2F shows another alternative configuration of the discontinuous coating of the dressing of the invention.

Figure 3 is a perspective drawing with parts separated from another embodiment of the dressing of the invention, wherein the dressing further comprises a porous coating material covering the discontinuous coating. Figure 4 is a partial view, extensively enlarged and partially in section of a portion of the dressing of Figure 3. Figure 5 shows an apparatus for manufacturing the dressing of the invention. Figure 6 shows a perspective view in separate parts of an adhesive bandage of the invention. Figure 7 is a side view of the bandage of Figure 6 wherein the bandage further comprises peel-off tabs. Fig. 8 is a schematic showing the manufacture of the bandage of Fig. 7. Fig. 9 is a longitudinal section of another embodiment of the bandage of Fig. 7, wherein the porous lining material has portions extending downward and portions thereof. of tongue that extend laterally.

DETAILED DESCRIPTION OF THE INVENTION The absorbent substrate in the dressing of the invention is useful as a passive dispenser that delivers at least one ingredient to the skin, such as, for example, the site of a wound. As used herein the term "passive dispenser" means that an active ingredient, eg, therapeutic ingredient, when present in the absorbent substrate, is only sparingly dispersed, if at all, from the substrate in the absence of moisture. When moisture, such as that contained in the exudate of a wound for example, comes into contact with the absorbent substrate, it causes the dissolution of any active ingredient present in the absorbent substrate, thereby allowing the active ingredient to migrate towards the skin or the surface of the wound. The discontinuous coating in the dressing of the invention, is useful as an active dispersant of at least one active ingredient of the inventive dressing. As used herein, the term "active dispersant" means that an active ingredient, when present in the discontinuous coating, is readily available from the skin by mere contact, even in the absence of moisture, blood or wound exudate. In the absence of moisture, it is thought that the active ingredients present in the batch coating are more readily available to the skin than those present in the absorbent substrate due to the higher diffusion rates of an active ingredient in the semi-solid and semi-liquid composition, the discontinuous coating, with respect to the slower diffusion rates present in a layer of solid absorbent substrate.

Although the compositions used in the discontinuous coating in the dressing of the invention may possess some degree of tackiness, the discontinuous coating is substantially non-adherent to the skin. This means that the dressings of the invention would not adhere sufficiently to the skin to remain in place during use, without other components such as a gauze cover or a backing coated with adhesive. The non-adherent nature of the coating composition ensures that the dressings of the invention are easily removable from a wound when it is desired to remove them without adversely affecting the healing wound. Figure 1A and Figure 1B show an embodiment of the apposite of the invention in top plan view, and in cross section along the line 2-2 of Figure 1A, respectively. The dressing 15 comprises an absorbent substrate 20 having a skin facing surface 25 and an opposing surface 30. The dressing 15 further comprises a discontinuous coating 35 covering a portion of the surface of the absorbent substrate 20. In the embodiment shown in FIG. 1, the liner is shown in the form of strips 40 of equal width arranged in a regular pattern, equally spaced apart from the skin facing surface 25 of the absorbent substrate 20. Although FIG. 1 B shows the liner 35 covering the surface of the absorbent substrate 20 without penetrating below said surface, it will be understood that the coating 35 may partially penetrate the absorbent substrate 20 as long as a quantity of the coating 35 covers at least some portion of the skin facing surface 25 of the substrate 20. The coating 35 may be applied to the substrate 20 in a regulated pattern or in a random pattern. For example, the liner 35 may be configured in a regular or random pattern of elements such as straight lines, angled lines, curved lines, intersecting lines, dots, circles and geometric shapes, or in a combination of these elements. Figures 2A to 2F show alternative embodiments of the dressing of the invention, wherein the covering is configured with a series of lines or bands parallel to the longitudinal axis of the dressing (Figure 2A), as a series of lines or bands at an angle to the apposite axis (Figure 2B), as a series of curved bands (Figure 2C), as a series of intersecting lines in a shaded pattern (Figure 2D), as a swirling line (Figure 2E), and as a series of dots (figure 2F). The coating can be applied to the substrate using techniques well known in the art such as printing, spraying, inverted roller coating or roller coating or extrusion coating techniques. The absorbent substrates used in the dressings of the invention can be selected from woven fabrics, spun fabrics, non-woven fabrics, and foams. A nonwoven fabric is the preferred substrate for use in the dressings of the invention.

By applying the coating composition to the substrate in a discontinuous pattern, a portion of the surface of the absorbent substrate facing the skin is exposed to the skin to allow absorption of fluid such as wound exudate from the absorbent substrate. . In order to provide the relief effects of the coating composition, but still provide access to the surface of the absorbent substrate, the coating composition must be applied to cover from about 1% to about 99% of the surface area of the absorbent substrate that it was facing. the skin. Preferably, the coating should cover from about 10% to about 90% of the surface area of the skin-facing absorbent substrate. More preferably, the coating should cover from about 20% to about 80% of the surface area of the substrate absorbent that looks towards the skin. The apposites of the invention may also comprise a porous coating material that covers the discontinuous coating. A dressing of the invention comprising a porous coating material is illustrated in Figures 3 and 4. The dressing 50 comprises an absorbent substrate 20 and a discontinuous coating 35 covering a portion of the surface 25 of the substrate 20. The dressing further comprises porous coating material 45 covering the coating 35. The porous coating material 45 may comprise a mesh, network or porous polyethylene film, an example of which is available from Hercules, Inc., of Wilmington, Del., U.S.A. under the designation DELNET X-550. Other porous coating materials can be used in place of the porous polyethylene films, mentioned above available under the name DELNET. For example, the porous coating material can be made of polyvinyl chloride, polypropylene, polyester, nylon, or similar polymeric materials, instead of polyethylene. It will be understood that in some cases, depending on factors such as the manufacturing conditions used and the rheological characteristics of the composition comprising the discontinuous coating 35, part of the coating composition can pass up the hole 55 of the porous coating material. and can diffuse to a certain extent on the upper surface 60 of the porous coating material 45. Portions of the composition that has diffused on the upper surface of the porous coating material are identified by number 65 in Figure 4. The material of porous coating 45 is shown in Figure 3 and Figure 4 as substantially coextensive with the absorbent substrate 20. It will be understood that the porous coating material can extend beyond the top surface of the dressing, and along the sides 70, 75 of absorbent substrate. The porous coating material 45 can also extend around the substrate 20, so that it is in contact with the second surface 30 of absorbent substrate 20.

The porous coating material 45 is shown in Figure 3 and Figure 4 extending through the composition comprising the discontinuous coating 35 and not in direct contact with the upper surface 25 of the substrate 20. It will be understood that the coating material The porous layer 45 can, in fact, come into direct contact with the portions of the upper surface 25 of the substrate 20. The degree to which the porous coating material 45 comes into direct contact with the surface 25 of the substrate, will depend on factors such as coating thickness, the degree to which the coating covers the surface of the substrate, the coating pattern and the stiffness of the porous coating material. The compositions comprising the coatings used in the dressings of the invention, preferably contain a hydrophobic solvent or a combination of hydrophobic solvent and other additives, resulting in a structured dressing that does not flow easily. The structured dressings of this invention can comprise an oil phase composition or a water in oil emulsion. The compositions can be hydrophobic or hydrophilic, although hydrophobic and / or oleophilic compositions are preferred in the dressings of the invention. The hydrophobic solvent can be a hydrocarbon material, such as petrolatum, mineral oil, or the like. It may also be composed of fatty acid-derived materials such as castor oil, or the like. Alternatively, the hydrophobic constituent solvento may contain a wax in addition to other solvents, such as paraffin wax, microcrystalline wax, beeswax, or the like. The hydrophobic solvent functions as the "oil base" of the composition or emulsion, and constitutes a large proportion of the composition, up to about 90% by weight. This solvent imparts ointment-like "feel" to the composition, contributes to the regularization of the supply of active materials, such as therapeutic ingredients that may be present in the composition, and is the means by which the dressings of this invention achieve characteristics. superior of wound release. Preferably, the solvent is a fluid, semi-solid or solid at room temperature or skin temperature (from about 12.7 ° C to about 37.7 ° C), which has a viscosity of about 1 to about 100,000 centipoises. In this way, any hydrocarbon material or combination of materials having the appropriate viscosity at the desired temperatures can be used in the products of this invention. As will be apparent to those skilled in the art, to avoid that the compositions used in the dressings of the invention migrate beyond the outer perimeter of the dressing during storage and use, the compositions preferably have a viscosity of at least about 10,000 centipoise. at physiological temperatures. More preferably, the compositions have a viscosity of at least about 20,000 centipoise, and more preferably, the compositions have a viscosity of at least about 30,000 centipoise at physiological temperatures.

A combination of members of two kinds of polymers and / or additives is preferably added to the hydrophobic solvent to obtain the compositions used in the dressings of this invention. The first class of polymers can be referred to generally as "network" polymers, these polymers increase the viscosity of the solvent or emulsion, and provide gel strength to the solvent or emulsion. The second class of polymers or additives can generally be referred to as "flow control" polymers or additives, which help control the flow characteristics of the compositions used in the dressings of this invention. The gel strength can be measured by the relationship between the viscosity of the composition and the temperature. The network polymers show a "plateau" in this type of measurement, i.e., the viscosity of the composition exhibits little or no change over a wide temperature range. The value of the viscosity in these plateaus is defined as the gel strength. Preferably, in the compositions used in the dressings of this invention, the gel strength should be from about 1,000 to about 10,000 poises on a temperature scale of about 50 ° C to about 95 ° C. Gel strength is particularly important in the manufacture and processing of wound dressings and sterile dressings, especially if high temperatures are encountered in the manufacturing process. If the dressings or bandages are going to be subjected to sterilization at high temperature (approximately 80 ° C - 82 ° C), as would be the case with sterilization with ethylene oxide, for example, the dressings of the invention must be able to withstand said temperatures without causing the structured ointment compositions to flow rapidly in the primary package or in the uncoated regions of the absorbent substrate. Such rapid flow could compromise sterility, or otherwise adversely affect the absorption characteristics of the dressing. Alternatively, it will be recognized that the difficulties of high temperature sterilization can be avoided by switching to low temperature sterilization techniques such as sterilization with irradiation. Preferably, the polymers that are useful in the compositions used in the dressings of this invention to create gel strength are block copolymers. Polystyrene and synthetic rubber two-, three- and multiple-arm block copolymers are especially useful as network polymers in the dressings of this invention. The rubber block of the block copolymer mentioned above is preferably a polymer of isoprene, ethylene-butadiene, ethylene-propylene, and the like, or combinations thereof. Examples of such polymers are the two and three block KRATON copolymers, commercially available from Shell Chemical Company, and the like. KRATON polymers are described by Shell as elastomers having a combination of high strength and low viscosity. These polymers contain block segments of monomeric ethylene units and monomeric rubber units. KRATON, G-1702, a two-block copolymer of ethylene and (ethylene-propylene), is especially useful in this regard. Polyacrylic acids that are slightly interlaced such as CARBOPOLs, commercially available from B.F. Goodrich, are also useful as network polymers in the products of this invention. Polyacrylic acids of this type and other polymers such as polyethylene oxide, cellulosics and polysaccharides, act as network polymers, and may also contribute to maintaining moisture in the wound. The polymer series Aguasorb-D are modified guar gums available from Hercules Corporation, and are examples of modified polysaccharides that are useful in the compositions used in the dressings of this invention, to maintain gel strength. Preferably, a polyacrylic acid CARBOPOL that would be useful in the compositions used in the dressings of this invention is CARBOPOL 934P, an acrylic acid polymer crosslinked with allyl sucrose. The second class of polymers or additives useful in the compositions used in the dressings of this invention are the "flow control polymers", which are chosen to help control the fluidity of the composition at room temperature or a nearby temperature to the same. These materials also aid in the ability of film formation, producing a more film-like structure to the apposites of this invention, as opposed to a gel-like structure. The characteristics similar to a film are important because they provide greater integrity to the dressing under manufacturing conditions. Nevertheless, the fluidity should not be so great that it allows the compositions to migrate from their desired positions on a dressing, while the dressing is in use in a wound. Agents for flow control, polymers or additives useful in the compositions of this invention also help achieve an "ointment sensation" in the dressings of the invention. This "ointment sensation" can be quantified as the value of the loss compliance and elastic shear adherence of the compositions measured at skin temperature (approximately 35 ° C) at a test frequency of 10 radians / second, measured in a Rheometrics RDS 7700 rheometer. Petrolatum, for example, has a very high shear compliance, greater than 5x10"5 cm2 / dyne, and has a loss compliance greater than 1x10" 5 cm2 / dyne. Although the petrolatum has an "ointment feel", it is also extremely fluid, and therefore unacceptable for use by itself in the dressings of this invention. The balance of "controlled flow" and "ointment sensation" is within the following desirable range of shear compliance: the elastic compliance ranges from approximately 2x10"6 to approximately 20x10" ® cm2 / dina and the loss compliance varies from approximately 3x10"® at approximately 20x10" 6 cm2 / dyne. Above this scale, the compositions may have an ointment sensation, but their fluidity is very high. Below this scale the flow is well controlled, but the composition has a considerably reduced ointment feel. The desired controlled flow balance and ointment sensation is achieved within this scale. Preferably, the polymers for flow control help to ensure that, at low temperatures, the dependence of the compositions on the viscosity is linear on a semi-log plot. This indicates that the compositions used in the dressings of this invention have a controlled and predictable viscosity at temperatures of use and room temperature. Polymers for flow control that help control flow at room temperature are preferably selected from polymers such as polyolefins. The polymers for flow control are preferably homopolymers, copolymers or polymers formed of several monomers, and are preferably non-interlaced. More preferably, this second class of polymers or additives includes the following: polyvinyl acetate; ethylene vinyl acetate copolymer; polyalkylenes such as polyisobutylene, ethylene-propylene and polyethylene copolymers, and the like. The three-block copolymers of polyethylene and synthetic rubber mentioned above for use as network polymers, also appear to function as polymers for flow control. KRATON G-1650, a three-block copolymer of ethylene, ethylene-butadiene and styrene, is especially useful in this regard. Additives or flow control polymers can also affect the "stickiness" of the composition, imparting tackiness or eliminating stickiness of the composition, depending on the polymers chosen and their concentrations. For example, polyethylenes added at a concentration of at least about 5% may help to eliminate tackiness of a composition, while an ethylene vinyl acetate copolymer added at a concentration of at least about 5% may increase tackiness of the composition. the composition. Other additives may also be introduced into the compositions used in the dressings of the invention to influence the "feel" of the final product. The composition preferably mimics the feeling of ointment products as best as possible, to ensure that the consumer who is accustomed to the prior ointment products feels comfortable using the dressing comprising the composition. For example, silicone waxes, common emollients known to those skilled in the art (eg, polyethylene glycol esters, more preferably having fatty acids such as functional end groups of stearate or palmitate), fatty acid esters such as stearate esters or palmitate, fatty alcohols such as stearic alcohol, or the like, can be used for this purpose in the dressings of the invention. Wax 580 from Dow Corning, available from Dow Corning Corp., of Midland Ml, is a mixture of stearoxytrimethylsilane and sterile alcohol. This wax is especially useful to improve the ointment sensation of the composition by reducing the drag created by the net and the polymers for flow control.

The dressings of the invention are ideally suited to release one or more active ingredients such as therapeutic ingredients to the surface of the skin. Illustrative classes of active ingredients that can be delivered to the skin by the dressings of the invention include antibiotics, analgesics, antipyretics, antimicrobials, antiseptics, antiallergics, anti-acne ingredients, anesthetics, anti-inflammatories, hemostats, cosmetics, vitamins, vasodilators, emollients, regulators of pH, antipruritics, anti-irritants, anti-histamines and steroids. Specific active ingredients that can be delivered to the skin by the dressings of the invention include chlorhexidine, neomycin sulfate, polymyxin-B sulfate, zinc bacitracin, benzalkonium chloride, cetylpyridinium chloride, buivacaine, tetracaine, cincaine, lidocaine, benzocaine , silver sulfadiazine, hydrocortisone, methandienone, trypsin, tolasolin, heparin, pramoxin, Aloe vera, tretinoin, retinol, retinaldehyde, menthol, capsaicin, alpha hydroxy acids and vitamins such as vitamin E. When contained in the dressings of the invention, one or more active ingredients may be contained mainly or exclusively in the absorbent substrate of the dressing, or mainly or exclusively in the composition used in the discontinuous coating. Alternatively, the active ingredients can be distributed in the absorbent substrate and in the discontinuous coating of the dressing. When multiple active ingredients are contained in the dressings of the invention, all active ingredients may be present in the coating composition and the substrate. Alternatively, certain active ingredients may be predominantly or exclusively present in one phase (e.g., the substrate), while other active ingredients may be present predominantly or exclusively in the other phase (e.g., the coating). The dressings of the invention contain two different regions or phases from which the active ingredients can be dispensed by two different mechanisms. The active ingredients contained in the coating composition are dispensed from the dressing by an active mechanism, in which the active ingredients are readily available to the skin even in the absence of moisture. The active ingredients are dispensed from the absorbent substrate portion of the dressing by a passive mechanism, whereby the active ingredients are released from the substrate mainly in the presence of moisture such as wound exudate. Therefore, it is possible to design apposites that are formulated specifically to take advantage of these different mechanisms. For example, one embodiment of the dressing of the invention contains active ingredients for the relief of the skin, for example, Aloe Vera, and hemostatic active ingredients. Since hemostatic agents are only necessary in the presence of an active ingredient, i.e., hemorrhagic wound, hemostatic agents are desirably incorporated into the substrate portion of the dressing, from which they can be activated by blood or exudate from the wound. wound. In contrast, the relief agent can be incorporated into the dressing portion of the dressing so that it is available at the wound site during the subsequent wound healing phase after the wound exudation has ceased. The ability to locate an active ingredient in different portions of a dressing also allows the construction of a dressing containing active ingredients that could be mutually incompatible. For example, active ingredient A may be contained in the substrate portion of the dressing, while active ingredient B, which is incompatible with active ingredient A, may be contained in the dressing portion of the dressing. An example of such a dressing is one that incorporates the active ingredients bacitracin zinc and benzalkonium chloride. Although these ingredients are mutually incompatible when they are present together in a single phase, a dressing that incorporates the ingredients in different phases is expected to be stable, for example, zinc bacitracin in the coating composition, and benzalkonium chloride in the substrate material. The technique for separating two or more active ingredients between different portions of a dressing provides means for making apposites in which two or more incompatible active ingredients are made accessible to a wound from the same dressing, in a way that was not available until now in the apposites of the prior art. The compositions used in the dressings of the invention can be advantageously colored with dyes or other coloring agents. Since the bandages of the invention can be made in principle with a variety of different active ingredients intended to achieve a variety of different functions, the ability to code the color of the compositions, provides an easy method to differentiate different compositions, both during the manufacture as in use by consumers. As indicated above, the compositions used in the coatings in the dressings of the invention are substantially non-adherent to the skin. Accordingly, during use, the dressings can be held adjacent to the skin by wrapping a tape such as gauze around the portion of the body containing the dressing. Alternatively, and preferably, the dressing of the invention forms part of an adhesive bandage in which the dressing is secured to a reinforcing material coated with adhesive. Reinforcing materials useful in the bandages of the invention include monolithic films, apertured films, foams, woven fabrics, non-woven fabrics, and mixed materials thereof. In the case of films, the reinforcement may be formed of any of the polymers known to be useful as reinforcing materials. Such polymers include plasticized PVC, polyolefins such as polyethylene or polypropylene, and polyurethane. Perforated or apertured films are the preferred reinforcing materials for the bandages of the invention.

The invention will now be illustrated by the following examples. The examples are illustrative only, and are not intended to limit the scope of the invention.

EXAMPLE 1 Preparation of the coating composition A semi-solid coating composition was obtained by transferring 1450.9 kg of super white petrolatum (Penreco, Division of Pennzoil Products Company, Karns City, Pennsylvania) into a stirred and heated tank of 3785 I. 0.18 kg of hydroxytoluene was added. butylated (PMC, Inc., Rocky River, OH). The tank was heated to 135 ° C with mixing, and 127.12 kg were added. of Kraton G1702 (Shell Chemical Company, Houston, Texas) and 36.32 kg of Kraton G1650 (Shell). The ingredients were then mixed for 3 hours at 135 ° C, at which point the mixture was completely homogeneous. The mixture was allowed to cool overnight to room temperature. The next morning, the mixture was reheated to a temperature of about 110 ° C with mixing. 181.6 kg of 580 wax was added from Dow Corning (Dow Corning Corp., Midland Michigan), preheated to 82.2 ° C. 1.81 kg of vitamin E acetate (Hoffmann-La Roche, Paramus, NJ) was added followed by 18.16 kg of mineral oil extract number 101, an extract of Aloe vera mineral oil (Florida Food Products, Inc., Eustis, Florida ). The mixture was mixed at approximately 110 ° C for one and a half hours until homogeneous. The mixture was discarded in storage cylinders, where it was allowed to cool to room temperature. The mixture had the following composition: * A mixture of stearoxytrimethylsilane and stearyl alcohol EXAMPLE 2 Preparation of a continuous roll of dressing of the invention, by discontinuous coating of the ointment composition on an absorbent substrate The equipment used to apply a discontinuous coating of the ointment composition to a tape of the absorbent substrate in the preparation of the dressings and bandages of the invention, is shown in Figure 5. A 18.92 liter bucket of the ointment composition of Example 1 was placed in a Bulk Melter Applicator Model 505 (Nordson Corp., Boothwyn, Pennsylvania) (not shown). The crucible comprised a platinum heater that heats the top surface of the ointment composition contained in the bucket. The stage was heated to a temperature of approximately 56.1 ° C to melt the composition contained in the uppermost portion of the cube. The ointment composition was pumped by means of a gear pump (not shown) located in the melter-applicator via line 86 to slot die 88. Die 88 was maintained at a temperature of 53.3 ° C during the coating operation. A 2.21 cm wide network of absorbent substrate 80 was pulled from a supply roll using a conventional unwinding system (not shown). The net was a nonwoven perforated redi comprising 65% rayon fibers and 35% polyamide fibers coated with a low density polyethylene coating on one side thereof. The net had a basis weight of 140 g / m2 and a thickness of 0.85 mm, and was available as non-woven M1541 from the Freudenberg Company of Weinheim, Germany. Before coating with the ointment composition of Example 1, the network of substrate material was preimpregnated with benzalkonium chloride at an addition of 0.045 mg / cm 2 by immersing the network in a 0.46% solution of benzalkonium chloride in water, passing through the network between clamping rollers to remove excess benzalkonium chloride solution and dry the network in a heating furnace. The network was removed from a supply roll contained in a conventional netting / tensioning apparatus of the type well known in the art (not shown). Subsequently, it was directed around the roller 82 to the roller 84. The ointment composition was extruded from the die 88 in the form of 4 strips, each of which was 0.39 cm wide, the distance between the strips was 0.15 cm, to the uncoated side of the absorbent nonwoven substrate 80. The ointment was applied on the net substrate 80 to a coating weight of 3.96 g per linear meter. Following the coating with the ointment composition, the network passed through a controlled temperature chamber 90 containing cooled air at -12.2 to -1.1 ° C to cool the network to room temperature. The net was then directed to the take-up roller 96 where it was wound onto a reel together with a layer of interline material 94 composed of silicone-coated release paper pulled from a supply roll 92.

EXAMPLE 3 One embodiment of a bandage of the invention An adhesive bandage is made using the dressing described in example 2. This adhesive bandage is illustrated in figure 6 of the drawings. The adhesive bandage 100 comprises a backing material 105 having openings 106 therein; an absorbent substrate 110; a discontinuous coating of an ointment-like composition 115; and a porous cover material 120. The upper surface 105a of the backing material is coated with a layer of acrylic adhesive 107 pressure sensitive. It will be understood that any of the adhesives well known in the art for use in adhesive bandages can be used in place of this adhesive. The adhesive can be deposited, if desired, on the backing layer in a continuous or discontinuous pattern instead of as a total coating as illustrated in the drawing. As illustrated further in the drawings, the substrate material 110 is preferably provided in the form of a fibrous pad which is centered end to end of the backing material and extends from one side of the backing material to the other. The substrate material 110 is secured to the backing material by the adhesive 107 mentioned above. It will be understood that the substrate material may comprise non-woven fabrics different from those described above. In addition, other materials may be used, such as foams, non-woven fabrics (eg, gauze), spun fabrics and the like. Alternatively, the substrate material may be covered or wrapped with a thin layer of nonwoven material or with a porous network, film or grid. As will also be seen in the drawings, the upper surface 110a of fibrous substrate material 110 carries and has the ointment-like composition 115 adhered thereto. The composition is coextensive in width with the substrate material 110 but is discontinuous in its length. In addition to absorbing the wound exudate, the substrate material functions to support the ointment-like composition that covers its top surface. In addition, the absorbent substrate material tends to provide a desirable damping effect when the adhesive bandage is applied over a wound site. Because the ointment-type composition is discontinuously coated on the surface of the absorbent substrate, the substrate is available to absorb moisture-containing fluids such as wound exudate during use. The top surface 115a of the ointment-like composition 115 is covered by a porous cover material 120. In the specific embodiment of this example, the porous cover material 120 comprises a porous polyethylene film available from Hercules, Inc. Wilmington, Del. , USES under the designation DELNET X-550. Other porous cover materials can be used in place of the porous polyethylene films mentioned above available under the name DELNET. For example, the porous cover material can be made of polyvinyl chloride, polypropylene, polyester, nylon or similar polymeric materials instead of polyethylene. The ointment-like composition 115 that is used in the adhesive bandage 100 of this example is the composition set forth in the aforementioned Example 1. The occlusive composition 115 is applied to the substrate material 110 according to the procedure set forth in Example 2 below. The porous cover material 120 covers the upper surface 115a of the occlusive composition 115 and is coextensive in length and width with the underlying substrate material 110. The release tabs 125, 126 comprising silicone-coated polystyrene are placed on the portions of the adhesive 107 and the top surface of the porous cover material 120 in the manner shown in Figure 7 of the drawings. The adhesive bandage shown in Figure 7 is made according to a method in which the bandage is oriented at right angles to the direction of travel of the supply materials through the manufacturing apparatus. Briefly, as shown in Figure 8, the backing material 105 coated with adhesive 107 is transported, from right to left as seen in Figure 8, on top of a conveyor belt (not shown). A network 150 comprising the substrate material 110 on which the ointment-like composition 115 has previously been applied by the extrusion coating process of Example 2 is pulled from the roll 155 and placed on top of the backing material coated with adhesive 105. The porous cover material 120 is pulled from the roll supply roll 160 and placed over the top of the net 150. It will be understood that in the process being described, the width of the cover material 120 substantially corresponds to the width of the net 150. The release material 120, supplied from the roll 165, is bent to the configuration shown in Figure 7 and applied to the area of adhesive exposed on one side of the backing material coated with adhesive. The release material 125, supplied from the roll 170, is then applied as to cover the area of adhesive exposed on the other side of the backing material coated with adhesive as well as the top surface of the porous cover material 120. The release material 125 extends beyond the edge of the porous cover material to provide a securing tab 125a as illustrated in Figure 7 of the drawings. The combined raw materials, assembled as just described, are then passed through the grip of cutting rollers 175, 176. The rollers 175, 176 perform two functions, i.e., compress the previously assembled supply materials to a pressure of 0.70-1.40 kg / cm2 and at the same time, cut the supply materials that pass, assembled in individual adhesive bandages 100. The individual adhesive bandages are subsequently wrapped, packaged and sterilized, all according to well procedures known in the art. The manner of making the bandages as described herein above gives rise to bandages in which the width of the dressing is coextensive with the width of the bandage. In alternate embodiments, the bandages of the invention comprise dressings in which the bandages are coextensive in length or width with their apposite contents. Rather, in these modalities, the dressing is narrower in width and shorter in length than the backing material covered with adhesive to which it is adhered. In such configurations, those bandages are called "island bandages" or "island bandages" and are also considered to be within the scope of the bandages and dressings of the invention.

EXAMPLE 4 Another embodiment of the bandage of the invention. Referring next to Figure 9, another embodiment of an adhesive bandage 200 of the invention in which the porous cover material 120 has been given an alternate configuration is illustrated in longitudinal section. As is the case with the adhesive bandage 100 illustrated in Figure 6, the adhesive bandage 200 comprises the backing 105; the adhesive layer 107; the absorbent substrate material 110; ointment-type composition 115; and porous cover material 120. In the bandage 100 illustrated in Figure 6, the porous cover material 120 was coextensive in length and width with the fibrous substrate material 110. In the alternate embodiment illustrated in the figure 9, the porous cover material 120 comprises downwardly extending portions 122a, 122b and longitudinally extending tongue portions 123a, 123b. The downwardly extending portions 122a, 122b serve to cover the ends 112a, 112b, respectively, of the fibrous substrate material 110 and the ends 117a, 117b, respectively, of the ointment-like composition 115. As will be seen by reference to 9, the ends 112a and 117a face the end edge 200a of the adhesive bandage 200, while the ends 112b and 117b face the end edge 200b of the adhesive bandage. The tongue portion 112a and 117b of the porous cover material 120 extends longitudinally for a short distance, e.g., about 0.07 cm, toward the end edge 200a of the bandage 200 while the tongue portion 123b extends a short distance toward end edge 200b. The advantage of providing the porous cover material 120 with downwardly extending portions and tongue portions 122a and 122b is that the longitudinal movement of the ointment-like composition 115 (i.e. movement toward either or both ends 200a, 200b of the bandage 200 ) is substantially avoided. In addition, this configuration of porous cover material 120 helps to ensure that the substrate material 110 remains firmly in its centered location between the ends 200a, 200b.

EXAMPLE 5 Microbiocidal activity of the bandage of the invention comprising benzalkonium chloride. The purpose of this test was to determine whether the efficacy of the benzalkonium chloride contained within the absorbent substrate of a bandage of the invention would be adversely affected when a portion of the surface facing the skin of the absorbent substrate contains a discontinuous coating. of an ointment type composition. The samples tested were the bandages of Example 4 comprising the dressing of Example 2. The 2.5 cm x 2 cm test samples were cut from the bandages as to remove the longitudinally extending strip-like adhesive portions extending further. beyond the limits of the dressing portion of the bandage. The microbiocidal activity of benzalkonium chloride in the dressing was tested by placing samples of the dressing on a peptone-casein-soybean-agar culture medium contained in petri dishes that have an area of 64 cm 2 that have been inoculated with certain microorganisms. The test samples were placed on the plates so that the side facing the skin of the dressing comes in contact with the agar medium. The following microorganisms were used: The bactericidal suspensions for seeding the prepared petri dishes were taken from cultures in their exponential growth phase. The concentration of each suspension was determined according to a standard method of AFNOR (Association Francaise Normalisation) using spectrophotometry at 620 nm. The suspensions of the desired concentration were then prepared by successive dilution to give the sowing supply solutions. A standard volume of the sowing supply solution was placed in the center of each prepared petri dish and extended with the aid of an extender. The inoculated dishes were dried in a drying oven at 37 ° C for 30 minutes. The dressings were placed on top of the middle in the manner described above, and the petri dishes were then incubated for a total of 24 to 48 hours at 37 ° C. The dishes were removed from the incubator periodically and the degree of bacterial growth below the dressing was measured. The results are indicated in the following table: * cfu = units of formation of colonies. TMTC = too many to count, indicating the marginal effect of the antiseptic on the microorganism. 0 = no growth of colonies below the dressing. The bactericide in the dressing is effective against the microorganism. Dif = diffusion of the antiseptic beyond the limit of the dressing to kill colonies adjacent to the dressing. The test results indicate that the benzalkonium chloride antiseptic in the dressing and bandage of the invention exhibit significant bactericidal activity against all microorganisms tested with the exception of Pseudomonas aeruginosa. This is not surprising, because quaternary antiseptics such as benzalkonium chloride are known to be less effective against Pseudomonas in relation to other microorganisms. The results indicate that the coating of the ointment-like composition on the absorbent substrate does not decrease the activity of the active ingredient contained within the substrate. The antiseptic on the substrate remains completely effective, indicating that in contrast to the prior art dressings in which the coating composition is continuously coated on a support, the discontinuous coating on the dressing of the invention allows access to the underlying substrate and to the substrate. active ingredients contained therein.

Claims (2)

NOVELTY OF THE INVENTION CLAIMS

1- A dressing comprising: a) an absorbent substrate having a first surface facing the skin and a second opposing surface; and b) a discontinuous coating of a semi-solid composition having an ointment-like feel that covers a portion of the first surface of the absorbent substrate; wherein said absorbent substrate is useful as a passive dispenser of at least one active ingredient, said coating is substantially non-adherent to the skin, and said coating is useful as an active dispenser of at least one active ingredient.

2 - The dressing according to claim 1, further characterized in that said discontinuous coating is configured in a regular pattern comprising selected elements of straight lines, angled lines, curved lines, lines that are traversed, points, circles and geometric shapes. 3. The dressing according to claim 1, further characterized in that said discontinuous coating is configured in a random pattern comprising selected elements of straight lines, angled lines, curved lines, intersecting lines, points, circles and geometric shapes . 4. - The dressing according to claim 1, further characterized in that said absorbent substrate is selected from non-woven fabric, spunbond, non-woven fabric and foam. 5. The dressing according to claim 4, further characterized in that said absorbent substrate comprises non-woven fabric. 6. The dressing according to claim 1, further characterized in that said discontinuous coating is provided with one or more colors. 7. The dressing according to claim 1, further characterized in that said discontinuous coating covers from 1% to 99% of the area of the first surface of the absorbent substrate. 8. The dressing according to claim 7, further characterized in that said discontinuous coating covers from 10% to 90% of the area of the first surface of the absorbent substrate. 9. The dressing according to claim 8, further characterized in that said discontinuous coating covers from 20% to 80% of the area of the first surface of the absorbent substrate. 10. The dressing according to claim 1, further comprising a porous cover material covering the discontinuous coating. 11. A dressing comprising: a) an absorbent substrate having a first surface facing the skin and a second opposing surface; b) a discontinuous coating of a semisolid composition having an ointment-like feel that covers a portion of the first surface of the absorbent substrate; c) at least one active ingredient designed to provide a therapeutic benefit to the skin; wherein the absorbent substrate is useful as a passive dispenser of at least one active ingredient, said coating is substantially non-adherent to the skin, and said coating is useful as an active dispenser of at least one active ingredient. 12. The dressing according to claim 11, further characterized in that the at least one active ingredient is selected from antibiotics, analgesics, antipyretics, antimicrobials, antiseptics, antiallergics, anti-acne, anesthetics, anti-inflammatory, emostat, cosmetics, vitamins, vasodilators , emollients, pH regulators, antipruritics, contrairritants, antihistamines and steroids. 13. The dressing according to claim 11, further characterized in that the at least one active ingredient is selected from chlorhexidine, neomycin sulfate, polymyxin-B sulfate, zinc bacitracin, benzalkonium chloride, cetylpyridinium chloride, bupivacaine, tetracaine, cincaine, lidocaine, benzocaine, silver sulfadiazine, hydrocortisone, methandienone, trypsin, tolazoline, heparin, pramoxin, aloe vera, tretinoin, retinol, retinaldehyde, methol, capsaicin, alpha hydroxy acids and vitamin E and its derivatives. 14. - The dressing according to claim 11, further characterized in that the at least one active ingredient is contained mainly in the absorbent substrate. 15. The dressing according to claim 11, further characterized in that the at least one active ingredient is contained mainly in the discontinuous coating. 16. The dressing according to claim 11, further characterized in that a portion of the at least one active ingredient is contained in the absorbent substrate and a portion of the at least one active ingredient is contained in the discontinuous coating. 17. A dressing comprising: a) an absorbent substrate having a first surface facing the skin and a second opposing surface; b) a discontinuous coating of a semi-solid composition having an ointment-like feel that covers a portion of the first surface of the absorbent substrate; c) a first active ingredient substantially contained within the absorbent substrate, and d) a second active ingredient substantially contained within the discontinuous coating; wherein the absorbent substrate is useful as a passive dispenser of at least one active ingredient, the coating is substantially non-adherent to the skin, the coating is useful as an active dispenser of at least one active ingredient and the active ingredients are designed to provide one or more therapeutic benefits to the skin. 18. - The dressing according to claim 16, further characterized in that the active ingredients are selected from antibiotics, analgesics, antipyretics, antimicrobials, antiseptics, antiallergics, anti-acne, anesthetics, anti-inflammatories, hemostats, cosmetics, vitamins, vasodilators, emollients, pH regulators , antipruritics, contrairritantes, antihistamines and steroids. 19. The dressing according to claim 17, further characterized in that said active ingredients are selected from chlorhexidine, neomycin sulfate, polymyxin-B sulfate, zinc bacitracin, benzalkonium chloride, cetylpyridinium chloride, bupivacaine, tetracaine, cincaine. , lidocaine, benzocaine, silver sulfadiazine, hydrocortisone, methandione, trypsin, tolazoline, heparin, pramoxin, aloe vera, tretinoin, retinol, retinaldehyde, menthol, capsaicin, alpha hydroxy acids and vitamin E and its derivatives. 20. The dressing according to claim 17, further characterized in that said first active ingredient is an antiseptic and the second active ingredient is selected from antipruritics, antibiotics, anesthetics, anti-inflammatories or mixtures thereof. 21. The dressing according to claim 20, further characterized in that the second active ingredient is an antipruritic. 22. - The dressing according to claim 17, further characterized in that the first active ingredient comprises benzalkonium chloride and the second active ingredient comprises aloe vera. 23. The dressing according to claim 22, further characterized in that said discontinuous coating further comprises vitamin E or one or more of its derivatives. 24. An adhesive bandage comprising: a) an absorbent substrate having a first surface facing the skin and a second opposing surface; and b) a discontinuous coating of a semi-solid composition having an ointment-like feel that covers a portion of the first surface of the absorbent substrate; c) a backup material; and d) a layer of adhesive on a surface of the backing material, the adhesive layer securing the absorbent substrate to the backing material; wherein said absorbent substrate is useful as a passive dispenser of at least one active ingredient, said coating is substantially non-adherent to the skin, and said coating is useful as an active dispenser of at least one active ingredient. 25. The bandage according to claim 24, further characterized in that said discontinuous coating is configured in a regular pattern comprising selected elements of straight lines, angled lines, curved lines, intersecting lines, dots, circles and geometric shapes . 26. - The dressing according to claim 24, further characterized in that said discontinuous coating is configured in a random pattern comprising selected elements of straight lines, angled lines, curved lines, intersecting lines, points, circles and geometric shapes. 27. The bandage according to claim 24, further characterized in that said absorbent substrate is selected from woven fabric, spunbond, non-woven fabric and foam. 28. The bandage according to claim 27, further characterized in that said absorbent substrate comprises non-woven fabric. 29. The bandage according to claim 24, further characterized in that said discontinuous coating covers from 1% to 99% of the area of the first surface of the absorbent substrate. 30. The bandage according to claim 29, further characterized in that said discontinuous coating covers from 10% to 90% of the area of the first surface of the absorbent substrate. 31- The bandage according to claim 30, further characterized in that said discontinuous coating covers from 20% to 80% of the area of the first surface of the absorbent substrate. 32. The bandage according to claim 24, further comprising a porous cover material covering the discontinuous coating. 33. - An adhesive bandage comprising: a) an absorbent substrate having a first surface facing the skin and a second opposing surface; b) a discontinuous coating of a semi-solid composition having an ointment-like feel that covers a portion of the first surface of the absorbent substrate; c) at least one active ingredient designed to provide a therapeutic benefit to the skin; d) a backup material; and e) a layer of adhesive on a surface of the backing material, the adhesive layer securing the absorbent substrate to the backing material; wherein said absorbent substrate is useful as a passive dispenser of at least one active ingredient, said coating is substantially non-adherent to the skin, and said coating is useful as an active dispenser of at least one active ingredient. 34. The bandage according to claim 33, further characterized in that the at least one active ingredient is selected from antibiotics, analgesics, antipyretics, antimicrobials, antiseptics, antiallergics, antiacne, anesthetics, anti-inflammatory, hemostats, cosmetics, vitamins, vasodilators, emollients. , pH regulators, antipruritics, contrairritants, antihistamines and steroids. 35. The bandage according to claim 33, further characterized in that the at least one active ingredient is selected from chlorexidine, neomycin sulfate, polymyxin-B sulfate, zinc bacitracin, benzalkonium chloride, cetylpyridinium chloride, bupivacaine, tetracaine , cincaine, lidocaine, benzocaine, silver sulfadiazine, hydrocortisone, methandione, trypsin, tolazoline, heparin, pramoxin, aloe vera, tretinoin, retinol, retinaldehyde, menthol, capsaicin, and alpha and hydroxy acids and vitamin E and its derivatives. 36. The bandage according to claim 33, further characterized in that the at least one active ingredient is contained primarily in the absorbent substrate. 37. The bandage according to claim 33, further characterized in that the at least one active ingredient is contained mainly in the discontinuous coating. 38. The bandage according to claim 33, further characterized in that a portion of the at least one active ingredient is contained in the absorbent substrate and a portion of the at least one active ingredient is contained in the discontinuous coating. 39. An adhesive bandage comprising: a) an absorbent substrate having a first surface facing the skin and a second opposing surface; b) a discontinuous coating of a semi-solid composition having an ointment-like feel that covers a portion of the first surface of the absorbent substrate; c) a first active ingredient substantially contained within the absorbent substrate; d) a second active ingredient substantially contained within the discontinuous coating; e) a backup material; and f) a layer of adhesive on a surface of the backing material, said layer of adhesive securing the absorbent substrate to the backing material; wherein said absorbent substrate is useful as a passive dispenser of at least one active ingredient, said coating is substantially non-adherent to the skin and said coating is useful as an active dispenser of at least one active ingredient and said active ingredient is designed for provide one or more therapeutic benefits to the skin. 40. The bandage according to claim 39, further characterized in that said active ingredients are selected from antibiotics, analgesics, antipyretics, antimicrobials, antiseptics, antialergics, antiacne, anesthetics, anti-inflammatories, hemostats, cosmetics, vitamins, vasodilators, emollients, regulators of pH, antipruritics, contrairritantes, antihistamines, and steroids. 41. The bandage according to claim 39, further characterized in that said active ingredients are selected from chlorhexidine, neomycin sulfate, polymyxin-B sulfate, zinc bacitracin, benzalkonium chloride, cetylpyridinium chloride, bupivacaine, tetracaine, cincaine , lidocaine, benzocaine, silver sulfadiazine, hydrocortisone, methandione, trypsin, tolazoline, heparin, pramoxin, aloe vera, tretinoin, retinol, retinaldehyde, menthol, capsaicin, alpha hydroxy acids and vitamin E and its derivatives. 42. The bandage according to claim 39, further characterized in that said first active ingredient is an antiseptic and the second active ingredient is selected from antipruritics, antibiotics, anesthetics, anti-inflammatories or mixtures thereof. 43. - The bandage according to claim 42, further characterized in that said second active ingredient is an antipruritio. 44. The bandage according to claim 39, further characterized in that said first active ingredient comprises banzalconium chloride and the second active ingredient comprises aloe vera. 45. The bandage according to claim 44, further characterized in that said discontinuous coating further comprises vitamin E or one or more of its derivatives.